+188.3%
AMAT vs MRNA
+444.4%
-256.1%
-39.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.8% | -3.4% | +2.5% | -0.8% |
| 7D | +6.9% | -10.1% | +17.0% | +7.0% |
| 30D | -10.1% | +126.7% | -136.8% | -11.9% |
| 3M | -6.0% | +184.1% | -190.1% | -14.5% |
| 6M | +38.6% | +143.3% | -104.6% | +29.3% |
| YTD | +83.1% | +359.9% | -276.8% | +52.8% |
| 1Y | +188.3% | +454.2% | -265.8% | +127.9% |
| All | +188.3% | +444.4% | -256.1% | +127.9% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling